تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Gilead Sciences Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $187.2B | |
|---|---|---|
| P/E (forward) | 15.4x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $27.31B | $27.28B | $27.12B | $28.75B | $29.44B | +1.9% |
| Gross profit | $20.70B | $21.62B | $27.12B | $22.50B | $23.21B | +2.9% |
| Operating income | $9.92B | $7.33B | $7.61B | $1.66B | $10.02B | +0.3% |
| Net income | $6.23B | $4.59B | $5.67B | $480.0M | $8.51B | +8.1% |
| EPS (diluted) | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 | +8.3% |
| EBITDA | $11.33B | $8.85B | $7.61B | $4.43B | $13.58B | +4.6% |
| R&D | $4.60B | $4.98B | $5.72B | $5.91B | $5.80B | +6.0% |
| SG&A | $5.25B | $5.67B | $6.09B | $6.09B | $5.77B | +2.4% |
Recent company headlines from major financial publishers.
FY2027 analyst consensus estimates support higher revenue and adjusted earnings. Growth then slows because HIV concentration limits the evidence for a longer expansion.
Improvement beyond FY2027 requires a larger non-HIV contribution and strong free cash flow. These are scenario conditions, while the cited evidence records FY2025 levels. Lower cell-therapy sales or weaker free cash flow would disconfirm this path.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 4.9% | $166 | $180 | $199 | $228 | $276 |
| 5.9% | $143 | $151 | $160 | $174 | $192 |
| 6.9% | $128 | $133 | $140 | $146 | $155 |
| 7.9% | $117 | $120 | $124 | $129 | $134 |
| 8.9% | $109 | $111 | $114 | $117 | $121 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |